Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.

3-D Rendering Red Blood Cells
Sierra announced data from the Phase III MOMENTUM study of momelotinib in myelofibrosis • Source: Shutterstock

Sierra Oncology, Inc. is hoping to take a sizable chunk of the market for myelofibrosis (MF) with Phase III data showing positive results for its JAK inhibitor momelotinib in patients who previously received JAK inhibitor treatment, a setting that has few therapy options. Still, how physicians use it and other JAK inhibitors may boil down to patient phenotype.

Data from the MOMENTUM trial, which Sierra announced 25 January, showed that the drug achieved statistically significant benefit on myelofibrosis...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.